Oncimmune reports lung cancer test data

Oncimmune Ltd. (Nottingham, U.K.) said its EarlyCDT-Lung test had sensitivities of 36%, 39% and 37%, respectively, and specificities of 91%, 89% and 90% in three cohorts of patients with newly diagnosed lung cancer in a validation study (n=145, 241, and 269). Additionally, there was no significant difference between different lung cancer stages detected by the test, which detected both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Data were published in Annals of Oncology. ...